We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.075 | -3.26% | 2.225 | 4,610,295 | 15:15:43 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.20 | 2.25 | 2.30 | 2.225 | 2.30 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -3.98M | -0.0035 | -6.34 | 25.35M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:55 | O | 1,500,000 | 2.215 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/11/2023 | 16:53 | ALNC |  TRADING UPDATES: Upland Resources completes technical study at Sarawak |
| 28/11/2023 | 12:19 | UKREG | Hemogenyx Pharmaceuticals PLC Placing to Raise GBP534,375 |
| 27/11/2023 | 10:52 | ALNC | Hemogenyx shares up as says CBR platform a potential cancer treatment |
| 27/11/2023 | 07:00 | UKREG | Hemogenyx Pharmaceuticals PLC CBR Expanded to Treatment of Cancer |
| 15/11/2023 | 15:43 | ALNC | Hemogenyx Pharmaceuticals completes lentivirus re-manufacture |
| 15/11/2023 | 07:00 | UKREG | Hemogenyx Pharmaceuticals PLC Lentivirus Re-manufacturing Completed |
| 31/10/2023 | 07:00 | UKREG | Hemogenyx Pharmaceuticals PLC Total Voting Rights |
| 28/9/2023 | 13:24 | ALNC | EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens |
| 28/9/2023 | 11:28 | UKREG | Hemogenyx Pharmaceuticals PLC Half-year Report |
| 18/9/2023 | 13:37 | ALNC | TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers |
Hemogenyx Pharmaceuticals (HEMO) Share Charts1 Year Hemogenyx Pharmaceuticals Chart |
|
1 Month Hemogenyx Pharmaceuticals Chart |
Intraday Hemogenyx Pharmaceuticals Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/12/2023 | 10:19 | Hemogenyx- Official Thread | 420 |
| 28/11/2023 | 16:14 | HEMO | 8,772 |
| 14/3/2022 | 16:13 | HEMO 2020/21 Discussion MODERATED | 3,217 |
| 11/1/2022 | 12:16 | Hemogenyx - 2021 Entry to clinical status | 288 |
| 09/6/2021 | 14:22 | Hemogemyx - nomoderated | 25 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/12/2023 08:20 by Hemogenyx Pharmaceuticals Daily Update Hemogenyx Pharmaceuticals Plc is listed in the Finance Services sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 2.30p.Hemogenyx Pharmaceuticals currently has 1,141,999,321 shares in issue. The market capitalisation of Hemogenyx Pharmaceuticals is £25,352,385. Hemogenyx Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.34. This morning HEMO shares opened at 2.30p |
Posted at 29/11/2023 08:52 by apotheki Ditto picked up some more and below the placing price. When the mist clears LSE:HEMO potentially should resume it;'s northwards bullish run of late.... |
Posted at 28/11/2023 14:20 by dreamtwister the Company to accelerate the completion of work set out in the plan presented and agreed to by the FDA and to re-submit the Investigational New Drug ("IND") applicationSo their you are in Black & White,Hemogenyx has Not Re-Submitted the Application For the IND ! so investors can rule out the Possibility of going Clinical 2023. on the Grounds of a fresh application the FDA will Review within a 30 day timeframe so the fall of 2024 & not before Hemogenyx may participate or advance towards clinical trials, Investors may take into consideration that Dr sandlers Awarded Share options Will be Executed & Added to the Shares in Issue.on approval of the commencement of clinical trials. |
Posted at 28/11/2023 13:35 by apotheki Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"The markets have at last started to recognise the significant recent progress that the Company has made in the development of both HEMO-CAR-T and CBR platform . Today's Placing will enable the Company to progress with its ambitious schedule to move forward to clinical trials of this exciting potential treatment for AML as well as to further expand the use our CBR platform for the treatment of solid tumours." |
Posted at 27/11/2023 07:50 by apotheki About Hemogenyx Pharmaceuticals plcHemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. |
Posted at 27/11/2023 07:30 by apotheki CBR Expanded to Treatment of CancerChimeric Bait Receptor-programmed macrophages show promise for treatment of Non-Hodgkin Lymphoma Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that its Chimeric Bait Receptor ("CBR") platform can potentially be used in the treatment of cancers, in addition to the viral diseases extensively reported by the Company to date. The Company has demonstrated that human macrophages, a type of immune cells, programmed with a purpose designed CBR, were able to eliminate Non-Hodgkin Lymphoma ("NHL") derived cells with high efficiency in vitro. This result suggests that the Company may be able to develop an efficient treatment for people suffering from relapsed and/or refractory stage III/IV metastasized NHL. In addition, based on data derived from its testing of CBR in connection with NHL, the Company has reason to believe that the newly designed CBR construct can be adapted to target several solid tumours such as epithelial ovarian cancer as well as certain carcinomas. The Company has been able to speed up its R&D efforts dramatically by using Artificial Intelligence ("AI") based protein structure/interactio Moreover, the Company has previously reported that it is testing CBR against live infectious SARS-Cov-2, the virus causing COVID-19. The Company has received preliminary results of tests of CBR against this live infectious virus. The results show that human macrophage cells programmed with CBR against SARS-CoV-2 are effective in in vitro experiments. These tests are being conducted by an external team of scientists in a biological level three ("BSL-3") facility. Additional work will be conducted to further optimize the method of application of cells programmed with CBR, as well as to obtain results in vivo (i.e., in a live animal model). Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This is an exciting breakthrough in proving the versatility of our CBR platform, greatly widening its potential use against cancers, in addition to the original pursuit of combatting viral infections. We are extremely pleased to see that CBR can potentially be used to develop new treatments for cancers such as NHL, as well as potentially for solid tumours, which are a significant challenge for existing therapies. We have also made meaningful advances in proving CBR's potential viability in treating COVID-19 and other viruses. We are hugely encouraged by these recent developments, and I am proud of Hemogenyx Pharmaceuticals' team of scientists who achieved this leap forward." |
Posted at 08/9/2023 18:17 by ashleyjv TIDMHEMOHemogenyx Pharmaceuticals PLC 08 September 2023 Reach - non-regulatory 8 September 2023 Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") CBR Patent Application Update Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that its patent application number "WO2023168292 Chimeric Bait Receptors and Uses Thereof" was published on 7 September 2023 by the World Intellectual Property Organization ("WIPO"). It remains to be reviewed and approved by national patent authorities. |
Posted at 15/6/2023 05:31 by badger60 I find it incredible the amount of exposure that some (on LSE) have to this share. A few are wearing losses in the 100's of 1000's, and yet after 7 years of nil substantive company progress, they are now left holding onto a hope that the failed IND will be a given sometime soon..... after being blocked by the FDA.Nothing that Vlad promised has ever come to pass....and this (failed) IND is no exception. There's no guarantee that even if the IND issue is rectified that the share price will react that much. Huge amounts of money, time and luck are needed to commence phase work to commercialisation. Hemo is not capable of raising such amounts (Mint 60 Mio CLN debacle)......with an ongoing reducing share price which is currently not far away from hitting 1p. Good luck with your holdings......and I hope for once that Hemo actually delivers value added for its shareholders which is reflected in the share price Unfortunately, the past track record does not support the idea that it will. |
Posted at 04/4/2023 12:20 by bobdown2 Have filtered the repetitious ones. Same format here as the lse.This is easily checked. The share price was marked up this morning. It is now nearly knocking on the offer. I think we could see the spread widen upwards after a few buys. The placings mean you cannot do comparisons but hemo reached around 6 pence on the recent rise. News of more importance could put the share price at 5 pence. I topped up last week. Sub 2.00. The gains from these levels could be substantial. Watch the trades and not the idiots. |
Posted at 23/3/2023 13:49 by ashleyjv Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of a full set of analytical tests required to verify the quality of the cells manufactured during three Process Qualification ("PQ") runs of the end-to-end process for HEMO-CAR-T production. Each PQ run is an end-to-end process of the manufacture of HEMO-CAR-T cells. The PQ runs were carried out in the Company's current Good Manufacturing Practice ("cGMP") compliant clean rooms. They were followed by analytical release tests that were conducted both by the Company and a third party to ensure that manufactured HEMO-CAR-T cells comply with a set of required quality attributes. Among these attributes are viability, potency and sterility of the manufactured HEMO-CAR-T cells.The completion of the full set of analytical tests of all PQ runs is the last manufacturing requirement that is necessary for the submission of an Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA"), which is now in the course of preparation. The IND is needed to obtain authorization from the FDA to commence Phase I clinical trials of HEMO-CAR-T. All PQ runs as well as analytical tests data will be compiled for inclusion in the IND submission pack. |
Posted at 13/2/2023 15:53 by chimpychops81 BadgerIts been a while Still slagging HEMO off I see, even going strong after its started its move north. You do know that getting the IND app to FDA for CAR T will be monumental for the share price dont you? Going clinical? The actual route to commerciality. Some might say if HEMO hadnt raised on this share price rise then they would have been badly run. Companies always raise after big share price runs. Its pretty much standard. Dilution is inevitable yet you talk about it as if its just some bad option Vlad has picked? They have plenty of cash now, cash is king as they say. Vlad is the tightest man alive and has run HEMO on a shoe string budget for years. Cash burn continues to be a low risk area for HEMO. When companies raise you need to know where the money is going. This is not some lifestyle company needing cash for wages and to keep the lights on, money is being ear marked for project work across the HEMO portfolio. You are still droning on about not earning any income yet! You are correct, pretty everyone understands whats going on in the department. But HEMO are getting a lot closer to making some dosh now, a lot closer. Moving clinical, getting the nod from FDA. The fact that the drug sounds good/effective/safe and have all the correct procedures in place to test it properly reflects exceptionally well on HEMO. External consultants utilised to check the app prior to submission, further verifying the quality of HEMOs work. Exciting times! Why do you still post on here? Im just interested? It sounds very personal for you! You NEED to see HEMO fail. Im honestly worried for your mental health now because they are on the cusp of becoming a clinical junior pharma. Its a real milestone, even you have to admit that. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
